Expanding Our Mission: Clinical Lymphoma, Myeloma & Leukemia

with the interests of our readership. Since our debut as Clinical Lymphoma in June 2000, we have striven to provide physicians and healthcare professionals with the most up-to-date, clinically relevant information available to enhance their ability to provide optimal care for their patients. As our publication grew within the oncology space, our audience demanded that we address other hematologic malignancies as well. Thus, in September 2005, we added multiple myeloma content to the journal. Once again, to meet the growing demand from our readership, we are broadening our scope to include the leukemias. Clinical Lymphoma, Myeloma & Leukemia publishes original articles describing various aspects of clinical and translational research of hematologic malignancies. The journal is devoted to articles on the detection, diagnosis, and treatment of lymphoma, myeloma, leukemia, and related disorders including macroglobulinemia, amyloidosis, and plasma cell dyscrasias. We welcome original studies, comprehensive reviews, perspectives, and current trials on these topics. In order to ensure the highest quality manuscripts, beginning with this issue, we would like to welcome Dr. Jorge E. Cortés as our Editor-in-Chief for leukemia content along with Drs. Morton Coleman, Raymond Comenzo, Guillermo Garcia-Manero, Jeffrey Lancet, and Steven Treon as our newest associate editors. We are very excited to have them join our team and extremely grateful for their commitment to this new expansion. As you all know, individually they are each considered to be leaders in the field of hematologic malignancies, and collectively, they bring tremendous prestige and a wealth of experience to our publication. We also wish to thank our existing associate editors, who include Drs. Brian Durie, Francine Foss, Jonathan Friedberg, Morie Gertz, Jean-Luc Harousseau, Brad Kahl, John Leonard, and Sagar Lonial, as well as the staff of CIG Media Group, LP. It has been through their long-standing dedication and commitment that we have been able to make Clinical Lymphoma & Myeloma (and now with Leukemia) such an outstanding journal. We look forward to working closely with our editorial board and our readership to ensure that this expansion in the scope of Clinical Lymphoma & Myeloma is a successful one.